Bezuclastinib

Name: Bezuclastinib in Nonadvanced systemic mastocytosis: Economic impact of Nonadvanced systemic mastocytosis on families
Published: 2026-09-14T15:39:06-04:00

Nonadvanced systemic mastocytosis

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the second half of 2026
Last updated: September 17, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Nonadvanced systemic mastocytosis

Economic impact of Nonadvanced systemic mastocytosis on families

1 evidence topic · 1 source

Patient and caregiver employment burden

“patients and caregivers must take an unexpected leave of absence from work” (opens the source at this quote in a new tab)